ArticleBritish journal of haematology2020

Double-bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2.

Lúcia SillaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.